With the increasing prevalence of diabetes around the world, diabetic nephropathy is the most common type of chronic kidney disease (KDOQI, 2007; Zimmet et al., 2001). When uncontrolled diabetes persists for 15 to 25 years, the blood vessels in the kidneys are damaged, resulting in abnormal amounts of proteins, including albumin, leaking into the urine (ADA, 2013; CDA, 2012; NHS, 2011; NKUDIC, 2013). Because diabetic nephropathy is a complication of diabetes, and at least 90% of all diabetic cases are type 2 diabetes, the risk factors and common comorbidities for type 2 diabetes are also considered to be the same for diabetic nephropathy. The major risk factors for type 2 diabetes are family history, advancing age, obesity, and gestational diabetes. Hypertension and dyslipidemia are also the most commonly-occurring comorbidities in people with diabetic nephropathy (GlobalData, 2013b).
According to GlobalDatas forecast, the 7MM had 4,889,171 prevalent cases of diabetic retinopathy in 2012. There were 14.03 million total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the 7MM, there will be 19.87 million total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the 7MM by 2022, with an annual growth rate (AGR) of 4.16% during the forecast period.
- The diabetic nephropathy EpiCast Report provides an overview of the risk factors and epidemiological trends for diabetic nephropathyin the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the total prevalent cases of diabetic retinopathy in the diagnosed diabetic population segmented by age, (over 40 years of age) and sex. The diagnosed prevalent cases are then further segmented by the presence of comorbid hypertension.
- The diabetic nephropathy epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global diabetic nephropathy market.
- Quantify patient populations in the global diabetic nephropathy market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic nephropathy therapeutics in each of the markets covered.
Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 8
3.2.1 Poor glycemic control elevates the risk of diabetic nephropathy 8
3.3 Global Trends 9
3.3.1 US 9
3.3.2 5EU 10
3.3.3 Japan 11
3.4 Epidemiological Forecast for Diabetic Nephropathy (2012-2022) 11
3.4.1 Forecast Methodology 11
3.4.2 Sources Used 12
3.4.3 Sources Not Used 13
3.5 Epidemiological Forecast for Diabetic Nephropathy (2012-2022) 15
3.5.1 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Diabetes 15
3.5.2 Forecast Assumptions and Methods Diabetic Nephropathy 19
3.6 Epidemiology Forecast for Diabetic Nephropathy (2012-2022) 21
3.6.1 Total Prevalent Cases of Diabetic Nephropathy 21
3.6.2 Total Prevalent Cases of Diabetic Nephropathy by Age 23
3.6.3 Total Prevalent Cases of Diabetic Nephropathy by Sex 24
3.6.4 Total Prevalent Cases of Comorbid Hypertension in Total Diabetic Nephropathy 26
3.7 Discussion 27
3.7.1 Epidemiological Forecast Insight 27
3.7.2 Limitations of the Analysis 28
3.7.3 Strengths of the Analysis 29
4 Appendix 30
4.1 Bibliography 30
4.2 About the Authors 34
4.2.1 Epidemiologists 34
4.2.2 Reviewers 34
4.2.3 Global Director of Epidemiology and Health Policy 35
4.2.4 Global Head of Healthcare 36
4.3 About GlobalData 37
4.4 About EpiCast 37
4.5 Disclaimer 38
List of Table
Table 1: Classification of Patients Based on the Levels of Albuminuria for the Three Standard Tests 7
Table 2: 7MM, Sources of the Total Prevalence Data Used in the Analysis of Diabetic Nephropathy 12
Table 3: 7MM, Sources Excluded from the Analysis of Diabetic Nephropathy 14
Table 4: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, Ages
List of Chart
Figure 1: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, Ages
Make an enquiry before buying this Report
Please fill the enquiry form below.